Hypercoagulability

Slide 1 · Hypercoagulability

Inherited and acquired prothrombotic states

Mechanisms • Clinical consequences • Pathologic reasoning

Dr Abu Suraih Sakhri

MBBS, MD (Pathology)

www.abusuraihsakhri.com

Slide 2 · Learning objectives

Locate hypercoagulability within Virchow’s triad and explain its importance in venous thrombosis.

Compare common inherited variants with deficiencies of natural anticoagulants.

Classify major acquired prothrombotic states and explain why risk factors interact.

Trace antibody-mediated thrombosis in HIT, VITT and antiphospholipid syndrome.

Apply mechanistic reasoning to illustrative clinical presentations.

Slide 3 · An increased tendency to form clots

Core definition

Blood has an abnormally high propensity to clot.

Typical substrate

Altered coagulation factors or loss of anticoagulant control.

Clinical expression

Venous thrombosis is especially important.

Hypercoagulability is a predisposition; Thrombosis is its possible event.

Slide 4 · Virchow’s triad: Interacting contributors

Endothelial injury

Exposure or activation of procoagulant surfaces

Abnormal flow

Stasis and turbulence favor local clot formation

Hypercoagulability

Inherited or acquired shifts toward clotting

Interaction

One risk factor can amplify another

THROMBOSIS

Slide 5 · Why hypercoagulability matters in venous disease

Venous circulation

Stasis facilitates persistence of activated factors.

Many inherited thrombophilias present with deep venous thrombosis.

Venous thrombi may embolize to pulmonary arteries.

Arterial / cardiac circulation

Endothelial damage and altered flow often dominate.

Platelet activation is prominent at high shear.

Selected disorders, including APS and HIT, affect arteries too.

Slide 6 · Normal anticoagulant restraint

Activated coagulation

Clotting factors generate thrombin.

Natural inhibitors

Protein C, protein S and antithrombin restrain the cascade.

Hemostatic balance

Clot formation remains localized and regulated.

Hypercoagulability results when procoagulant drive increases or restraint is weakened.

Slide 7 · Two broad etiologic categories

Primary (genetic)

Variants in coagulation-factor genes.

Deficiencies of natural anticoagulants.

Rare defects of fibrinolysis or homocysteine metabolism.

Secondary (acquired)

Immobilization, injury or abnormal flow.

Estrogen exposure and disseminated cancer.

Immune-mediated states: HIT and APS.

Slide 8 · Genotype is not identical to thrombosis

Carriage of a thrombophilic variant confers susceptibility, not inevitable disease.

A common heterozygous variant may remain clinically silent throughout life.

Homozygosity or combined variants can impart greater thrombotic risk.

Acquired exposures may convert predisposition into a clinical event.

Risk is conditional on genotype, coexisting disorders and exposure.

Slide 9 · Inherited hypercoagulability: Mechanism map

More procoagulant activity

Factor V Leiden; Prothrombin G20210A; Increased clotting factors

Less inhibition

Antithrombin, protein C or protein S deficiencies

Less effective clearance

Rare fibrinolytic abnormalities

Different molecular defects converge on excessive thrombus formation.

Slide 10 · Genetic causes: Classification in the source

Source category

Representative abnormalities

Common

Factor V Leiden; Prothrombin G20210A

Common

Increased factors VIII, IX, XI or fibrinogen (genetic basis uncertain)

Rare

Antithrombin, protein C or protein S deficiency

Very rare

Fibrinolysis defects; Homozygous homocystinuria

Slide 11 · Activated protein C normally limits factor V

Factor Va

Participates in prothrombin activation.

Activated protein C

Proteolytically inactivates factor Va; Protein S supports this pathway.

Reduced amplification

The procoagulant signal is curtailed.

This inhibitory checkpoint is central to understanding factor V Leiden.

Slide 12 · Factor V Leiden: Resistance to inactivation

F5 variant

Arg506Gln substitution in factor V.

Protein C resistance

Factor V is less susceptible to cleavage and inactivation.

Persistent procoagulant effect

Natural antithrombotic regulation is reduced.

The source identifies this as a common inherited cause of venous thrombosis.

Slide 13 · Factor V Leiden: Risk is genotype dependent

Heterozygosity increases the relative risk of venous thrombosis.

Homozygous carriers have a greater susceptibility than heterozygotes.

Most otherwise healthy carriers do not develop a thrombotic event.

Interpret family or genetic findings alongside provoking circumstances.

Slide 14 · Factor V Leiden and a provoking exposure

Inherited predisposition

Factor V Leiden heterozygosity

Acquired exposure

Prolonged immobility or pregnancy

Thrombotic outcome

Deep venous thrombosis may occur

The inherited variant and acquired environment can cooperate rather than act separately.

Slide 15 · Prothrombin G20210A: The gene alteration

A single-nucleotide variant lies in the 3′ untranslated region of the prothrombin gene.

The alteration is associated with increased circulating prothrombin.

Elevated substrate availability favors thrombin generation.

It is another common inherited cause of venous thrombophilia.

Slide 16 · Prothrombin variant: Mechanistic sequence

Noncoding variant

Prothrombin G20210A

More prothrombin

Increased circulating precursor

Greater thrombotic tendency

Enhanced coagulation potential

The prothrombin variant differs mechanistically from factor V Leiden.

Slide 17 · Two common inherited variants

Factor V Leiden

Affects the factor V protein.

Conveys resistance to activated protein C.

Reduces normal inactivation of a coagulation cofactor.

Prothrombin G20210A

Variant occurs in a noncoding region.

Associated with higher prothrombin levels.

Increases substrate supporting coagulation.

Slide 18 · Antithrombin: A key plasma inhibitor

Antithrombin belongs to the normal anticoagulant defense system.

It limits activated coagulation enzymes, notably thrombin.

Deficiency decreases an important brake on the coagulation cascade.

The source classifies antithrombin deficiency as a rare inherited cause.

Slide 19 · Antithrombin deficiency: Loss of inhibition

Inherited deficiency

Less functional antithrombin activity

Insufficient inhibition

Activated clotting enzymes persist

Clinical propensity

Venous thrombosis; Possible recurrence

The source associates rare natural anticoagulant deficiencies with early and recurrent thromboembolism.

Slide 20 · Protein C deficiency: The regulatory defect

Protein C is part of a normal thrombin-regulated anticoagulant pathway.

When activated, it helps inactivate procoagulant factors.

Deficiency weakens feedback inhibition and favors clot propagation.

Inherited deficiency may present with venous thrombosis relatively early in life.

Slide 21 · Protein S deficiency: Reduced cofactor support

Protein S supports the anticoagulant effects of activated protein C.

Its deficiency impairs the efficiency of the protein C pathway.

The resulting tendency is toward venous thrombosis.

Protein S deficiency is listed among rare inherited thrombophilias.

Slide 22 · Inherited inhibitor deficiencies: Functional comparison

Deficient factor

Main conceptual defect

Expected consequence

Antithrombin

Less inhibition of activated enzymes

Persisting clotting activity

Protein C

Less proteolytic anticoagulant action

Reduced feedback control

Protein S

Less support for activated protein C

Impaired anticoagulant pathway

Slide 23 · Increased coagulation-factor levels

The textbook table includes increased factors VIII, IX and XI.

Increased fibrinogen is also categorized with common genetic predispositions.

The genetic explanations for these elevations are described as uncertain.

A high procoagulant-factor burden can tip balance toward clot formation.

Slide 24 · Rare disturbances of fibrinolysis

Fibrinolysis is the physiological pathway for removing fibrin-containing clots.

A defect in this system can impede thrombus clearance.

The textbook groups inherited fibrinolysis defects as very rare causes.

This is a mechanistic category rather than a single specified gene defect.

Slide 25 · Homocysteine: Inherited and acquired elevation

Inherited

Marked elevations may result from cystathionine β-synthase deficiency.

Homozygous homocystinuria is listed as very rare.

Biochemical elevation is not itself proof of thrombosis.

Acquired

Vitamin B₆, B₁₂ or folate deficiency may elevate homocysteine.

Some studies report prothrombotic effects; Others do not.

The source explicitly acknowledges uncertain causality.

Slide 26 · When should inherited causes enter the differential?

Age and presentation

Consider hereditary risk in thrombosis before age 50.

Phenotype

Recurrent venous thromboembolism increases concern.

Provoking factors

A triggering exposure does not exclude inherited susceptibility.

A provoking event and hereditary susceptibility can coexist.

Slide 27 · Case: Thrombosis during prolonged travel

HYPOTHETICAL TEACHING VIGNETTE

A 34-year-old develops a first lower-extremity DVT following prolonged immobility during travel. A relative had venous thrombosis at a young age.

Is the provoking exposure sufficient to exclude inherited susceptibility?

Which common inherited variants are relevant to the mechanism?

Slide 28 · Case discussion: Inherited plus acquired risk

HYPOTHETICAL TEACHING VIGNETTE

The vignette combines an environmental trigger with a possible hereditary susceptibility.

Reasoning

Immobility promotes stasis, while factor V Leiden or prothrombin G20210A can increase baseline coagulation tendency. The coexistence of both mechanisms is the intended inference; The vignette does not establish a genotype.

Slide 29 · Acquired states: Strong risk factors

Circulatory / injury

Systemic / immune

Prolonged bed rest or immobilization

Cancer

Myocardial infarction

Disseminated intravascular coagulation

Atrial fibrillation

Heparin-induced thrombocytopenia

Surgery, fracture or burn

Antiphospholipid syndrome

Prosthetic cardiac valves

—

Slide 30 · Other acquired thrombosis risk factors

Physiologic / hormonal

Medical / environmental

Pregnancy and postpartum

Nephrotic syndrome

Oral contraceptive use

Cardiomyopathy

—

Sickle cell anemia

—

Smoking

Slide 31 · Immobility: Abnormal flow meets coagulation

Reduced movement

Venous return becomes less effective.

Stasis

Activated factors are not efficiently diluted or washed out.

Thrombosis risk

Local clot formation becomes more likely.

Prolonged bed rest is a strong acquired thrombosis risk factor in the source.

Slide 32 · Cardiac conditions: Flow disturbance as a driver

Myocardial infarction

Noncontractile myocardium may promote local stasis.

Mural thrombus can form in regions of disturbed flow.

Injury and stasis may contribute more than a systemic coagulation defect.

Atrial fibrillation

Abnormal atrial contraction favors blood stasis.

Left atrial dilation can deepen flow disturbance.

Thrombosis reflects Virchow’s triad, not an isolated factor mutation.

Slide 33 · Tissue injury provides multiple prothrombotic signals

Operative injury

Vascular/tissue trauma and postoperative immobility

Fracture or burn

Tissue damage with local and systemic response

Trauma

Vascular injury and stasis may dominate mechanism

Acquired thrombophilia is frequently multifactorial.

Slide 34 · Hyperestrogenic states and thrombosis

Estrogen exposure

Pregnancy or oral contraceptives

Hepatic response

Increased coagulation-factor synthesis; Reduced anticoagulant synthesis

Altered balance

Increased thrombotic tendency

The textbook characterizes this proposed pathway as probable, not uniquely proven.

Slide 35 · Cancer-associated hypercoagulability

Disseminated malignancy

Tumor-related systemic effects

Procoagulant release

Tumors release mediators that promote coagulation.

Venous thrombosis

A major potential clinical consequence

In cancer, tumor procoagulants as a mechanism for thrombosis.

Slide 36 · Additional conditions in acquired thrombophilia

Nephrotic syndrome and cardiomyopathy appear’s acquired risk-factor table.

Sickle cell anemia may impede microvascular flow through deformed erythrocytes.

Hyperviscosity in polycythemia vera can promote small-vessel stasis.

The mechanisms differ; Their shared endpoint is increased thrombotic risk.

Slide 37 · Smoking, obesity and aging

Smoking and obesity are identified as acquired contributors to hypercoagulability.

The source notes that their precise prothrombotic mechanisms are not fully defined.

Advancing age may reduce endothelial prostacyclin (PGI₂) production.

Avoid assigning a single established pathway to a multifactorial exposure.

Slide 38 · Acquired thrombophilia is mechanistically heterogeneous

Stasis

Bed rest, atrial fibrillation, cardiac dysfunction

Vascular / tissue injury

Trauma, surgery, myocardial infarction

Coagulation activation

Cancer, pregnancy, immune-mediated conditions

Clinical risk factors may affect more than one arm of Virchow’s triad.

Slide 39 · Heparin-induced thrombocytopenia: Central paradox

HIT is an immune-mediated complication following heparin exposure.

Antibodies against platelet factor 4 (PF4)–heparin complexes activate platelets.

Platelet consumption produces thrombocytopenia.

At the same time, platelet activation promotes serious venous or arterial thrombosis.

Falling platelet counts do not imply protection against thrombosis.

Slide 40 · HIT starts with PF4–heparin immune complexes

PF4 release

Platelets release PF4 from α-granules.

Heparin binding

PF4 binds heparin and undergoes antigenic change.

IgG response

Antibodies recognize the altered PF4 complex.

The immunogenic PF4 complex is the trigger.

Slide 41 · HIT: Immune complex to platelet activation

Anti-PF4 IgG

Forms complexes associated with platelet surfaces

Fc-receptor activation

IgG-mediated activation of platelets

Procoagulant expression

Platelet-bound and soluble mediators favor thrombi

Some intermediate molecular details remain incompletely defined.

Slide 42 · HIT: The two consequences of antibody binding

Thrombocytopenia

Antibody-coated platelets are removed by macrophages.

Platelet counts fall.

This laboratory finding gives the syndrome its name.

Thrombosis

Immune-mediated platelet activation promotes coagulation.

Veins and arteries may both be affected.

Thrombosis is the more dangerous manifestation.

Slide 43 · HIT: Clinically serious complications

Venous thrombosis can develop during the immune response.

Arterial thrombosis may cause limb ischemia, stroke or myocardial infarction.

Skin necrosis and gangrene are described consequences.

Recognition matters because the complication can be life-threatening.

Slide 44 · HIT: Pathologic evidence and diagnostic framing

Exposure

History of heparin administration

Platelet phenotype

Thrombocytopenia with possible new thrombosis

Immune mechanism

Demonstration of anti–PF4–heparin antibodies

The source discusses antibody demonstration; It does not supply a complete testing algorithm.

Slide 45 · Heparin preparations and HIT risk

Unfractionated heparin

HIT after exposure to unfractionated heparin.

PF4–heparin complexes form the relevant antigenic substrate.

Other anticoagulants

Low-molecular-weight heparin causes HIT less frequently.

Direct factor Xa or thrombin inhibitors avoid heparin-associated PF4 complex formation.

Slide 46 · Vaccine-induced thrombotic thrombocytopenia (VITT)

An extremely rare syndrome described after certain adenoviral-vector COVID-19 vaccines.

Like HIT, VITT is characterized by antibodies to platelet factor 4.

The source attributes PF4 immunogenicity to interactions with some adenoviral proteins.

VITT may be life-threatening and requires prompt recognition.

Slide 47 · VITT: Anatomic distribution of thrombosis

Site

Potential clinical consequence

Cerebral venous sinuses

Venous obstruction, sometimes with hemorrhage

Deep leg veins

Deep venous thrombosis

Pulmonary arteries

Pulmonary thromboembolism

Splanchnic veins

Abdominal venous thrombosis

Slide 48 · HIT and VITT: Similarity is not identity

HIT

Typically follows heparin exposure.

Anti-PF4–heparin immune complexes are central.

Immune platelet activation causes thrombosis with thrombocytopenia.

VITT

Reported after certain adenoviral-vector vaccines.

Anti-PF4 antibodies arise without administered heparin.

Characteristic thromboses may occur in unusual venous beds.

Slide 49 · Antiphospholipid syndrome: Diagnostic concept

APS is an autoimmune prothrombotic condition associated with antiphospholipid antibodies.

Clinical expression includes venous or arterial thrombosis.

Pregnancy morbidity is another major manifestation.

An antibody result alone is not equivalent to the complete clinical syndrome.

Slide 50 · Primary and secondary APS

Primary APS

Characteristic thrombotic or obstetric features.

No established associated systemic autoimmune disorder.

Can present with varied vascular complications.

Secondary APS

Associated with a defined autoimmune disease.

Systemic lupus erythematosus is an important example.

Thrombotic and obstetric effects can overlap with primary APS.

Slide 51 · Antiphospholipid antibodies: Targets

These antibodies recognize phospholipids or associated proteins.

Cardiolipin is among the targets discussed in the source.

β₂-glycoprotein I binds avidly to phospholipid-containing cell surfaces.

Anti–β₂-glycoprotein I antibodies are implicated in the pathogenesis of APS.

Slide 52 · APS: Immune activation promotes thrombosis

Antiphospholipid antibodies

Binding to lipid-associated targets, including β₂-glycoprotein I

Cellular response

Activation of endothelium, neutrophils, monocytes and platelets

Prothrombotic state

Complement activation and impaired fibrinolytic activity contribute

The source describes the mechanisms as complex and incompletely understood.

Slide 53 · APS: Venous and arterial manifestations

Recurrent venous thrombosis may lead to pulmonary embolism.

Recurrent subclinical emboli can contribute to pulmonary hypertension.

Arterial events include stroke, bowel infarction and renovascular manifestations.

Cardiac valve vegetations and thrombocytopenia may accompany vascular disease.

Slide 54 · APS-associated pregnancy morbidity

Early fetal loss

The source emphasizes interference with trophoblast growth and differentiation.

Impaired placentation may occur without primary thrombotic causation.

Do not reduce all obstetric APS effects to placental clots.

Later pregnancy complications

Preeclampsia and preterm birth may develop.

Trophoblast dysfunction and inflammation contribute.

Antiphospholipid antibodies and complement have implicated roles.

Slide 55 · The lupus anticoagulant paradox

In vivo

Associated with an increased risk of thrombosis

In vitro

Phospholipid-dependent clotting assays can be prolonged

Clinical interpretation

Prolonged PTT is not proof of a bleeding disorder

Anticoagulant in the assay; Prothrombotic in the patient.

Slide 56 · APS: Why a positive antibody may be insufficient

Antiphospholipid antibodies may occur in apparently healthy individuals.

The source proposes that an additional prothrombotic stimulus may be required.

Infection, smoking and pregnancy are described as potential “second hits.”

Clinical manifestations and antibody findings must be interpreted together.

Slide 57 · APS: Serologic and clinicopathologic clues

The textbook bases diagnosis on clinical findings plus serum antibodies.

The lupus anticoagulant may prolong an in-vitro PTT.

Anticardiolipin reactivity can yield a false-positive syphilis serologic result.

Neither finding alone establishes a thrombotic event or a full clinical syndrome.

Slide 58 · HIT versus APS: Immune mechanisms differ

Feature

HIT

APS

Typical context

Heparin exposure

Autoimmune / idiopathic context

Antibody target

PF4–heparin complexes

Phospholipid-associated antigens

Cellular effect

Platelet activation

Multiple cell and complement pathways

Typical manifestations

Thrombocytopenia and thrombosis

Thrombosis and pregnancy morbidity

Slide 59 · Case: Thrombocytopenia with new thrombosis

HYPOTHETICAL TEACHING VIGNETTE

A hospitalized patient receives unfractionated heparin. A subsequent fall in platelets is accompanied by acute venous thrombosis.

How can thrombocytopenia coexist with a prothrombotic state?

Which immune complex provides the mechanistic explanation?

Slide 60 · Case discussion: Immune platelet activation

HYPOTHETICAL TEACHING VIGNETTE

The clinical pattern is compatible with the mechanism described for heparin-induced thrombocytopenia.

Reasoning

Anti-PF4–heparin IgG complexes can activate platelets while antibody-coated platelets are also removed by macrophages. Platelet count decline and thrombosis are parallel consequences, not contradictory findings.

Slide 61 · Case: Recurrent losses and venous thrombosis

HYPOTHETICAL TEACHING VIGNETTE

A woman has a history of recurrent pregnancy losses and an objectively confirmed lower-extremity venous thrombosis. Laboratory evaluation raises concern for antiphospholipid antibodies.

Which clinical domains define the APS phenotype in the source?

Why might an in-vitro PTT be prolonged?

Slide 62 · Case discussion: Antiphospholipid syndrome

HYPOTHETICAL TEACHING VIGNETTE

The vignette combines obstetric morbidity with a thrombotic phenotype.

Reasoning

APS involves antibodies against phospholipid-associated targets, with cell activation, complement engagement and effects on placentation. Lupus anticoagulant activity may prolong phospholipid-dependent assays despite prothrombotic clinical behavior.

Slide 63 · Mechanistic pattern recognition

Clue

Mechanism to consider

Young patient + VTE + provoking exposure

Inherited predisposition plus acquired risk

Heparin + falling platelets + thrombosis

Anti-PF4 immune platelet activation

Thrombosis + obstetric complications

Antiphospholipid-associated mechanisms

Cancer + new venous thrombosis

Tumor-related procoagulant activity

Immobilization + DVT

Venous stasis with additional risk factors

Slide 64 · Reasoning traps in hypercoagulability

Do not equate a thrombophilic genotype with certain future thrombosis.

Do not dismiss hereditary risk merely because immobilization or pregnancy is present.

Do not interpret HIT thrombocytopenia as a low-risk or bleeding-only state.

Do not interpret a prolonged lupus anticoagulant–related PTT as protection from clotting.

Do not assume APS pregnancy complications all result from placental thrombosis.

Slide 65 · Integrated take-home framework

Identify the milieu

Inherited predisposition, acquired exposures or both

Find the pathway

Excess procoagulants; Impaired inhibition; Immune activation

Predict the phenotype

Venous, arterial or obstetric manifestations

A mechanistic classification is more informative than a flat list of risk factors.

Slide 66 · Source and interpretation

Core source: Robbins, Cotran & Kumar, Pathologic Basis of Disease, 11th edition (2026), Chapter 4.

Primary topic: Hypercoagulability, printed pages 110–112; contextual hemostasis and altered-flow sections immediately preceding.

The lecture paraphrases the supplied source and uses original editable teaching schematics.

Illustrative vignettes are hypothetical. No clinical specimens or externally verified updates are represented.